Vistagen Therapeutics annual r&d spending
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Vistagen Therapeutics R&D Spending Growth & History (VTGN)
Vistagen Therapeutics's r&d spending was $55.0M for fiscal 2026.
View full Vistagen Therapeutics company overviewVistagen Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $55.0M | $15.6M | +39.62% |
| 2025 | 2025-03-31 | $39.4M | $19.4M | +96.66% |
| 2024 | 2024-03-31 | $20.0M | −$24.4M | −54.88% |
| 2023 | 2023-03-31 | $44.4M | $9.0M | +25.33% |
| 2022 | 2022-03-31 | $35.4M | $23.5M | +196.90% |
| 2021 | 2021-03-31 | $11.9M | −$1.4M | −10.83% |
| 2020 | 2020-03-31 | $13.4M | −$3.7M | −21.78% |
| 2019 | 2019-03-31 | $17.1M | $9.3M | +120.27% |
| 2018 | 2018-03-31 | $7.8M | $2.6M | +49.17% |
| 2017 | 2017-03-31 | $5.2M | $1.3M | +32.36% |
| 2016 | 2016-03-31 | $3.9M | $1.5M | +61.61% |
| 2015 | 2015-03-31 | $2.4M | −$47,900 | −1.93% |
| 2014 | 2014-03-31 | $2.5M | −$950,200 | −27.70% |
| 2013 | 2013-03-31 | $3.4M | −$2.0M | −36.33% |
| 2012 | 2012-03-31 | $5.4M | $1.7M | +46.50% |
| 2011 | 2011-03-31 | $3.7M | — | — |
Vistagen Therapeutics quarterly r&d spending
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $10.9M | −$772,000 | −6.61% |
| Q4 2026 | 2026-03-31 | $13.2M | $3.0M | +28.91% |
| Q3 2026 | 2025-12-31 | $14.2M | $2.9M | +25.81% |
| Q2 2026 | 2025-09-30 | $15.9M | $5.7M | +55.80% |
| Q1 2026 | 2025-06-30 | $11.7M | $4.0M | +52.69% |
| Q4 2025 | 2025-03-31 | $10.2M | $2.8M | +37.25% |
| Q3 2025 | 2024-12-31 | $11.3M | $6.8M | +149.17% |
| Q2 2025 | 2024-09-30 | $10.2M | $6.4M | +165.26% |
| Q1 2025 | 2024-06-30 | $7.6M | $3.5M | +82.23% |
| Q4 2024 | 2024-03-31 | $7.4M | −$1.9M | −20.35% |
| Q3 2024 | 2023-12-31 | $4.5M | −$2.3M | −33.81% |
| Q2 2024 | 2023-09-30 | $3.9M | −$9.0M | −70.13% |
| Q1 2024 | 2023-06-30 | $4.2M | −$11.1M | −72.55% |
| Q4 2023 | 2023-03-31 | $9.3M | −$2.9M | −23.68% |
| Q3 2023 | 2022-12-31 | $6.9M | −$925,000 | −11.89% |
| Q2 2023 | 2022-09-30 | $12.9M | $3.0M | +29.76% |
| Q1 2023 | 2022-06-30 | $15.3M | $9.8M | +180.16% |
| Q4 2022 | 2022-03-31 | $12.2M | $7.3M | +150.13% |
| Q3 2022 | 2021-12-31 | $7.8M | $4.3M | +122.51% |
| Q2 2022 | 2021-09-30 | $9.9M | $7.6M | +321.38% |
| Q1 2022 | 2021-06-30 | $5.5M | $3.7M | +215.27% |
| Q4 2021 | 2021-03-31 | $4.9M | $3.1M | +165.82% |
| Q3 2021 | 2020-12-31 | $3.5M | $481,600 | +15.98% |
| Q2 2021 | 2020-09-30 | $2.4M | −$1.8M | −43.92% |
| Q1 2021 | 2020-06-30 | $1.7M | −$2.6M | −59.87% |
| Q4 2020 | 2020-03-31 | $1.8M | −$1.9M | −51.04% |
| Q3 2020 | 2019-12-31 | $3.0M | −$2.3M | −43.50% |
| Q2 2020 | 2019-09-30 | $4.2M | −$1.1M | −20.07% |
| Q1 2020 | 2019-06-30 | $4.3M | $1.6M | +57.23% |
| Q4 2019 | 2019-03-31 | $3.8M | $1.1M | +42.46% |
| Q3 2019 | 2018-12-31 | $5.3M | $3.7M | +233.09% |
| Q2 2019 | 2018-09-30 | $5.3M | $2.8M | +116.81% |
| Q1 2019 | 2018-06-30 | $2.7M | $1.6M | +150.29% |
| Q4 2018 | 2018-03-31 | $2.6M | $1.5M | +127.22% |
| Q3 2018 | 2017-12-31 | $1.6M | −$9,200 | −0.57% |
| Q2 2018 | 2017-09-30 | $2.4M | $820,500 | +51.09% |
| Q1 2018 | 2017-06-30 | $1.1M | $270,500 | +32.76% |
| Q4 2017 | 2017-03-31 | $1.2M | $64,000 | +5.83% |
| Q3 2017 | 2016-12-31 | $1.6M | $804,700 | +99.80% |
| Q2 2017 | 2016-09-30 | $1.6M | −$50,000 | −3.02% |
| Q1 2017 | 2016-06-30 | $825,700 | $453,100 | +121.60% |
| Q4 2016 | 2016-03-31 | $1.1M | $141,000 | +14.75% |
| Q3 2016 | 2015-12-31 | $806,300 | $360,900 | +81.03% |
| Q2 2016 | 2015-09-30 | $1.7M | $1.1M | +197.01% |
| Q1 2016 | 2015-06-30 | $372,600 | −$101,000 | −21.33% |
| Q4 2015 | 2015-03-31 | $956,000 | $390,000 | +68.90% |
| Q3 2015 | 2014-12-31 | $445,400 | −$105,900 | −19.21% |
| Q2 2015 | 2014-09-30 | $557,600 | −$111,700 | −16.69% |
| Q1 2015 | 2014-06-30 | $473,600 | −$221,900 | −31.91% |
| Q4 2014 | 2014-03-31 | $566,000 | $227,000 | +66.96% |
| Q3 2014 | 2013-12-31 | $551,300 | −$568,300 | −50.76% |
| Q2 2014 | 2013-09-30 | $669,300 | −$437,000 | −39.50% |
| Q1 2014 | 2013-06-30 | $695,500 | $472,900 | +212.44% |
| Q4 2013 | 2013-03-31 | $339,000 | −$1.5M | −81.46% |
| Q3 2013 | 2012-12-31 | $1.1M | −$186,400 | −14.27% |
| Q2 2013 | 2012-09-30 | $1.1M | −$120,700 | −9.84% |
| Q1 2013 | 2012-06-30 | $222,600 | $1,500 | +0.68% |
| Q4 2012 | 2012-03-31 | $1.8M | −$36,691 | −1.97% |
| Q3 2012 | 2011-12-31 | $1.3M | $859,189 | +192.29% |
| Q2 2012 | 2011-09-30 | $1.2M | $535,084 | +77.33% |
| Q1 2012 | 2011-06-30 | $221,100 | −$453,682 | −67.23% |
| Q4 2011 | 2011-03-31 | $1.9M | — | — |
| Q3 2011 | 2010-12-31 | $446,811 | — | — |
| Q2 2011 | 2010-09-30 | $691,916 | — | — |
| Q1 2011 | 2010-06-30 | $674,782 | — | — |
Vistagen Therapeutics r&d spending trends
Over the last five fiscal years, Vistagen Therapeutics's r&d spending increased from $11.9M to $55.0M, a change of $43.0M. The latest reported quarter, Q1 2027, shows $10.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vistagen Therapeutics source filings ↗